Navigate Fool.com
Will TELK beat
the market?



Community Rating: 2 Stars: Unattractive

1.35 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.35
Previous Close $1.35
Daily Range $1.35 - $1.36
52-Week Range $1.05 - $2.15
Market Cap $6.2M
P/E Ratio -1.15
Dividend (Yield) $0.00 (0.0%)
Volume 7,017
Average Daily Volume 85,322
Current FY EPS $0.00

How do you think TELK
will perform against the market?

Top TELK Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


YeahBuddy79 (< 20)
Submitted May 6, 2008

Embarrassing at best. All the posts have already noted the deaths and that it kills people. As if that is not enough for you, this stock has a bad track record and it is falling faster then Cheney's a … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Worst Stock for 2008: Pfizer

Pfizer is a good company, but a bad stock for 2008.

Telik says early-stage trial data of lung cancer drug positive

Biogen Can't Find a Buyer

The pharma gives up its quest for bidders.

Neurochem's Crazy Choice

Neurochem chooses a risky path for its lead drug candidate.

7 Surprising 1-Star Stocks

These low-rated picks prove that a stock doesn't have to be loved to outperform.

World's Scariest Stock: Dendreon

Dendreon's scary future should make it an "underperform" in CAPS.

A Surprising Decision for Telik

It still doesn't look like its lead drug is helping anyone get better.

Following the Fallen Biotech Class of 2006

Ever wondered what happened to last year's biotech disaster stories?

More Misery for Neurochem

An unsurprising response from the FDA.

Get Ready for the Bounce

Who's fallen hardest? Who can bounce highest?

See More TELK News...





TELIK, INC. (TELK) Description

A biopharmaceutical company working to discover, develop and commercialize innovative small molecule drugs to treat diseases. Website: http://www.telik.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks